Lake Street affirms $60 target on Tandem Diabetes after Q3 results

Tandem Diabetes’ “strong momentum” continued during Q3 as revenue growth accelerated from 43.7% in Q1 to 60.0% in Q2 and 71.3% during Q3, Lake Street analyst Brooks O’Neil tells investors in a post-earnings research note. The analyst sees the strong results continuing into Q4 and affirms a buy rating on the shares with a $60 price target.
https://thefly.com/landingPageNews.php?id=2816635